Cover Image

HARDBACK
$59.95



View/Hide Left Panel

substance as to constitute a distinct entity. If the current level of intake is significantly above what has been traditionally recommended, then the level of concern should be increased.

REFERENCES

Altman DG. 1998. Statistical reviewing for medical journals. Stat Med 17:2661–2674.

Auriche M, Loupi E. 1993. Does proof of casualty ever exist in pharmacovigilance? Drug Safe 9:230–235.


Bannerman RH, Burton J, Wen-Chieh C, eds. 1983. Traditional Medicine and Health Care Coverage. A Reader for Health Administrators and Practitioners. Geneva: World Health Organization.

Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. 1998. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: Face-to-face interview with 515 users of herbal remedies. Br J Clin Pharmacol 45:496–500.

Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F. 1994. False-positives in spontaneous reporting: Should we worry about them? Br J Clin Pharmacol 38:401–404.

Blum MD, Graham DJ, McCloskey CA. 1994. Temafloxacin syndrome: Review of 95 cases. Clin Infect Dis 18:946–950.


CFSAN (Center for Food Safety and Applied Nutrition). 2001. Overview of Dietary Supplements. Online. Food and Drug Administration. Available at http://www.cfsan.fda.gov/~dms/ds-oview.html. Accessed February 22, 2002.

Chadwick DJ, Marsh J, eds. 1990. Bioactive Compounds from Plants. Ciba Foundation Symposium 154. New York: John Wiley and Sons.

Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, Wassilak SG. 1994. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12:542–550.

Chyka PA, McCommon SW. 2000. Reporting of adverse drug reactions by poison control centers in the US. Drug Safe 23:87–93.

CIOMS (Council for International Organizations of Medical Sciences). 1990. Standardization of definitions and criteria of causality assessment of adverse drug reaction. Drug-induced liver disorders: Report of an International Consensus Meeting. Int J Clin Pharmacol 28:317–322.

CIOMS. 1999. Guidelines for Preparing Core Clinical-Safety Information on Drugs, 2nd ed. Report of CIOMS Working Groups III and V. Geneva: CIOMS.

CIOMS. 2001. Current Challenges in Pharmacolvigilance: Pragmatic Approaches. Report of CIOMS Working Group V. Geneva: CIOMS.

Counsell C. 1997. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 127:380–387.


Dobelis IN. 1997. Magic and Medicine of Plants. A Practical Guide to the Science, History, Folklore, and Everyday Uses of Medical Plants. Pleasantville, NY: Reader’s Digest Association.


Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. 1998. Trends in alternative medicine use in the United States, 1990–1997: Results of a follow-up national survey. J Am Med Assoc 280:1569–1575.


Faich GA. 1986. Adverse-drug-reaction monitoring. N Engl J Med 314:1589–1592.

Farnsworth NR. 2003. NAPRALERT (Natural Products ALERT) Database. Chicago: University of Chicago.

FDA (Food and Drug Administration). 2003a. Current good manufacturing practice in manufacturing, packing, or holding dietary ingredients and dietary supplements. Proposed rule. Fed Regis 68:12157–12263.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement